80% of pharma companies have new product planning groups on brand commercialization committees during early-stage development
![](/46/pdcnewsitem/04/13/23/cuttinr%20edge%20info.jpg)
Internal functions are key for companies' committees across stages of development.
A new study of pharmaceutical brand teams found that during the preclinical and Phase I stages of development, 80% of surveyed companies' had new product planning (NPP) groups on their brand commercialization committees. The study, published by Cutting Edge Information, highlights the importance of NPP teams in transitioning products from development to market.
Clinical development, legal, and market research teams were also present in 60% of companies throughout the preclinical stage, while only 40% of firms had portfolio management teams in this phase. However, the involvement of portfolio management teams increased to 60% during the Phase 1 process and regulatory, supply, and marketing teams as well as competitive intelligence stakeholders were included 40% of the time during this development stage.
According to the study, Pharmaceutical Commercialization Profiles: Driving Brand Success with Better Budgeting and Timing, the majority of surveyed groups (83%) each involve clinical development, regulatory, market research, and medical affair groups during Phase 2. During this same stage of development, 50% of surveyed companies each include legal, portfolio management, and publication teams. More than half of companies represent each aforementioned function on brand committees throughout Phase 3. All surveyed organizations have regulatory, pricing and marketing stakeholders represented on these committees.
"Brand committees' stakeholder involvement and staffing changes throughout a product's lifecycle," said Adam Bianchi, senior director of research at Cutting Edge Information. "By combining stakeholders from across the company in these committee meetings, all internal teams become aware of upcoming actions or hurdles that the brand may face."
Pharmaceutical Commercialization Profiles: Driving Brand Success with Better Budgeting and Timing, provides signposts and key budget and staff metrics to help improve pharmaceutical brand commercialization strategies and resources. Report highlights include
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance